Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy

To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy. TTP is defined as time from the start of treatment date to the date the patient is first recorded as having disease progression, even in patients who discontinue study treatment early due to toxicity.

Study Overview

• Status: Completed
• Conditions: Androgen-independent Prostate Cancer
• Intervention / Treatment: Drug: cetuximab; Drug: Mitoxantrone

Detailed Description

This is a nonblinded, randomized phase II study to determine the activity of Novantrone (mitoxantrone) with or without Erbitux (cetuximab) in patients with androgen independent prostate cancer (AIPC) who have been treated previously with docetaxel chemotherapy. The Novantrone (mitoxantrone)-only treatment arm will serve as a concurrent control arm to aid in the determination of the benefit of the Novantrone (mitoxantrone)-Erbitux (cetuximab) combination in this setting.

Patients will be randomly assigned 2:1 to 1 of 2 treatment arms; 93 patients in Arm 1 and 47 patients in Arm 2. A balanced randomization procedure will be performed utilizing a code list that will be developed prior to the study opening. Because the patients will be stratified by performance status (ECOG 0 and 1 vs. ECOG 2), the list will be developed to ensure a balance between the 2 treatment arms.

• Study Type: Interventional
• Enrollment (Actual): 115
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85012
      • Hematology Oncology Associates
    • Sedona, Arizona, United States, 86336
      • Northern AZ Hematology & Oncology Assoc
  • Colorado
    • Denver, Colorado, United States, 80218
      • Rocky Mountain Cancer Center-Midtown
  • Florida
    • Melbourne, Florida, United States, 32901
      • Melbourne Internal Medicine Associates
    • New Port Richey, Florida, United States, 34655
      • Florida Cancer Institute - New Hope
    • Ocala, Florida, United States, 34474
      • Ocala Oncology Center
    • Ocoee, Florida, United States, 34761
      • Cancer Centers of Florida, P.A.
  • Illinois
    • Niles, Illinois, United States, 60714
      • Cancer Care & Hematology Specialists of Chicagoland
  • Indiana
    • Indianapolis, Indiana, United States, 46277
      • Central Indiana Cancer Centers
    • Terre Haute, Indiana, United States, 47802
      • Hope Center
  • Minnesota
    • Minneapolis, Minnesota, United States, 55404
      • Minnesota Oncology Hematology, P.A.
  • Missouri
    • Columbia, Missouri, United States, 65201
      • Missouri Cancer Associates
    • St. Joseph, Missouri, United States, 64507
      • St. Joseph Oncology, Inc.
  • Nevada
    • Las Vegas, Nevada, United States, 89169
      • Comprehensive Cancer Centers of Nevada
  • New Hampshire
    • Hooksett, New Hampshire, United States, 03106
      • NH Oncology-Hematology PA
  • New Jersey
    • Morristown, New Jersey, United States, 07960
      • Hematology-Oncology Associates of NNJ, P
  • New York
    • Albany, New York, United States, 12208
      • Albany Medical Cancer Center
    • Rochester, New York, United States, 14623
      • Interlakes Oncology Hematology, PC
  • North Carolina
    • Raleigh, North Carolina, United States, 27607
      • Cancer Centers of North Carolina
  • Ohio
    • Kettering, Ohio, United States, 45409
      • Greater Dayton Cancer Center
  • Oregon
    • Eugene, Oregon, United States, 97401
      • Willamette Valley Cancer Center
    • Portland, Oregon, United States, 97239
      • Oregon Health & Science University
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Cancer Centers of the Carolinas
  • Texas
    • Amarillo, Texas, United States, 79106
      • Texas Oncology, P.A. -Amarillo
    • Arlington, Texas, United States, 76012
      • Texas Oncology, P.A.
    • Austin, Texas, United States, 78731
      • Texas Oncology - Central Austin Cancer Center
    • Beaumont, Texas, United States, 77702
      • Mamie McFaddin Ward Cancer Center
    • Dallas, Texas, United States, 75246
      • Texas Oncology, P.A.
    • Dallas, Texas, United States, 75230
      • Texas Cancer Center at Medical City
    • Dallas, Texas, United States, 75231
      • Texas Oncology, P.A.
    • Dallas, Texas, United States, 75237
      • Methodist Charlton Cancer Ctr.
    • Denton, Texas, United States, 76210
      • Texas Cancer Center
    • El Paso, Texas, United States, 79915
      • El Paso Cancer Treatment Ctr
    • Ft. Worth, Texas, United States, 76104
      • Texas Oncology, P.A.
    • Garland, Texas, United States, 75042
      • Texas Oncology, P.A
    • Longview, Texas, United States, 75601
      • Longview Cancer Center
    • McAllen, Texas, United States, 78503
      • South Texas Cancer Center - McAllen
    • Mesquite, Texas, United States, 75150
      • Texas Cancer Center of Mesquite
    • Midland, Texas, United States, 79701
      • Allison Cancer Center
    • Odessa, Texas, United States, 79761
      • Texas Oncology - Odessa
    • Paris, Texas, United States, 75460
      • Paris Regional Cancer Center
    • Sherman, Texas, United States, 75090
      • Texas Cancer Center - Sherman
    • Sugar Land, Texas, United States, 77479
      • Texas Oncology Cancer Center-Sugar Land
    • Tyler, Texas, United States, 75702
      • Tyler Cancer Center
    • Webster, Texas, United States, 77598
      • Texas Oncology, P.A.
  • Virginia
    • Fairfax, Virginia, United States, 22031
      • Fairfax Northern VA Hem-Onc PC
    • Norfolk, Virginia, United States, 23502
      • Virginia Oncology Associates
    • Salem, Virginia, United States, 24153
      • Onc and Hem Associates of SW VA, Inc.
  • Washington
    • Burien, Washington, United States, 98166
      • Highline Medical Oncology
    • Edmonds, Washington, United States, 98026
      • Puget Sound Cancer Center-Edmonds
    • Kennewick, Washington, United States, 99336
      • Columbia Basin Hematology and Oncology
    • Seattle, Washington, United States, 98133
      • Puget Sound Cancer Center-Seattle
    • Spokane, Washington, United States, 99202
      • Cancer Care Northwest-South
    • Vancouver, Washington, United States, 98684
      • Northwest Cancer Specialists-Vancouver
    • Yakima, Washington, United States, 98902
      • Yakima Valley Mem Hosp/North Star Lodge

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the prostate. Note: Patients may have either measurable or non-measurable disease.
• Radiographic evidence of regional or distant metastases
• Current evidence of progression (by PSA and/or imaging studies) despite standard hormonal therapy.
• Progression by PSA will be defined as: A rising PSA defined as: at least 2 rises in PSA over a reference value (PSA #1). The first rising PSA (PSA #2) must be taken at least 1 week after PSA #1. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2. Progression for nonmeasurable disease will be defined as 2 or more new bone lesions; for measurable disease, progression will be defined by standard RECIST criteria.
• For patients who have been on antiandrogen therapy (ie, bicalutamide, flutamide, etc.), patients must have discontinued anti-androgen therapy for at least 6 weeks (4 weeks for flutamide) without evidence of an antiandrogen withdrawal response. A washout period will not be required for patients who did not respond to an antiandrogen prescribed as second line hormonal therapy. For patients whose progression is documented by PSA, the last required PSA must be after the required anti-androgen washout period (4-6 weeks as appropriate).
• One prior docetaxel-containing regimen. Patients must have received at least 2 doses in an every 3-week schedule or 6 doses on a weekly schedule of docetaxel. Patients may have discontinued therapy due to progression, intolerance, completion of planned therapy, or other reasons. Chemotherapy treatment with any second-line regimen will not be permitted. Patients who have been previously treated with a first-line docetaxel-based doublet regimen will be eligible for this study, (eg, patients treated on a prior first-line trial containing a docetaxel/carboplatin or other docetaxel-based doublet).
• Serum testosterone levels (See protocol for specific details) (unless surgically castrate). Patients must continue androgen deprivation with an LHRH agonist if they have not undergone orchiectomy
• ECOG performance status

• Laboratory criteria for entry:

  • absolute neutrophil count
  • platelets
  • bilirubin
  • AST or ALT
• Life expectancy greater than 3 months
• Age greater than or equal to 18 years
• Agree to use contraceptives while on study if sexually active, and for 2 months after the last dose of study drug.
• Has signed a Patient Informed Consent Form
• Has signed a Patient Authorization Form

Exclusion Criteria:

• More than 1 prior chemotherapy regimen for metastatic disease
• Prior history of uncontrolled congestive heart failure or left ventricular ejection fraction (LVEF) that is less than the institution's lower limit of normal on MUGA or echocardiogram
• A second active malignancy (diagnosed within 5 years) except adequately treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm
• Significant active concurrent medical illness or infection
• Treatment with chemotherapy for AIPC within the past 21 days
• Prior treatment with Novantrone (mitoxantrone)
• Prior therapy which specifically and directly targets the EGFR pathway
• Prior severe infusion reaction to a monoclonal antibody
• Recent myocardial infarction (within prior 6 months)
• Prior treatment with radionuclides, with the exception of prior treatment with samarium, which will be allowed provided at least 8 weeks have passed since administration.
• Is receiving concurrent immunotherapy, hormonal therapy, radiation therapy, or any other non-protocol therapy (excluding LHRH antagonist)
• Is receiving concurrent investigational therapy or has received such therapy within the past 30 days
• Has evidence of CNS involvement
• Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection.
• Is unable to comply with requirements of study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Erbitux (cetuximab) and Novantrone (mitoxantrone)	Drug: cetuximab; Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter; Other Names: Erbitux; Drug: Mitoxantrone; Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists; Other Names: Novantrone
Experimental: Arm 2; Novantrone (mitoxantrone)	Drug: Mitoxantrone; Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists; Other Names: Novantrone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Median Time to Progression (TTP)	TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
2-year Radiographically Evident Progression-free Survival (REPFS).	Radiographic progression: 1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture).	24 months.
Objective Response Rate (ORR)	ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.	24 months
Median Time to Prostate-specific Antigen (PSA) Progression	Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression.	24 months
Prostate-specific Antigen (PSA) Response Rate	Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later	24 months
Prostate-specific Antigen (PSA) Doubling Time	PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)]	24 months
Median Progression-free Survival (PFS)	PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.	24 months
Median Overall Survival (OS)	OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.	30 months

Collaborators and Investigators

• Sponsor: US Oncology Research
• Collaborators: Eli Lilly and Company; Oregon Health and Science University
• Investigators: Principal Investigator: Mark T. Fleming, MD, Virginia Oncology Associates/US Oncology

Publications and helpful links

General Publications

• Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Mar;10(1):6-14. doi: 10.1016/j.clgc.2011.11.003.

Study record dates

Study Major Dates

• Study Start: May 1, 2008
• Primary Completion (Actual): March 1, 2011
• Study Completion (Actual): June 1, 2011

Study Registration Dates

• First Submitted: April 4, 2008
• First Submitted That Met QC Criteria: April 14, 2008
• First Posted (Estimate): April 18, 2008

Study Record Updates

• Last Update Posted (Estimate): December 9, 2016
• Last Update Submitted That Met QC Criteria: October 13, 2016
• Last Verified: October 1, 2016

More Information

Terms related to this study

• Keywords: Androgen-independent prostate cancer(AIPC)
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Mitoxantrone; Cetuximab
• Other Study ID Numbers: 06-118